Scientific projects at the interface of discovery and disease


Experimental strategy for the identification of mTORC1 and 2 substrates in Glioblastoma multiforme (GBM) cell lines and tumors using quantitative multiplex mass spectrometry-based phosphoproteomics.

Experimental strategy for the identification of mTORC1 and 2 substrates in Glioblastoma multiforme (GBM) cell lines and tumors using quantitative multiplex mass spectrometry-based phosphoproteomics.

Research Project 1

Proteomic Approaches to Target the PP6-mTORC2 Pathway in Glioblastoma

Arminja Kettenbach, PhD

Glioblastoma multiforme (GBM) is the most common and aggressive tumor of the central nervous system in adults and it is generally fatal within 12 months of diagnosis. We propose to identify targets in the newly uncovered and frequently overexpressed PP6-mTORC2 pathway for the development of new therapeutic strategies to fight this devastating disease. 


Research Project 2

Identifying Mitophagy Receptors as Targets in Ras-dysregulated Cells

Michael Ragusa, PhD

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and challenging cancers to treat in the United States. The growth of PDAC tumors is dependent on a cellular degradation process, termed autophagy. We are combining biochemical and cellular approaches to uncover the role of autophagy in PDAC.

Saccharomyces cerevisiae were stained with MitoTracker Red CMXRos and imaged using a Zeiss LSM 880 with Airyscan to monitor mitochondrial dynamics.

Saccharomyces cerevisiae were stained with MitoTracker Red CMXRos and imaged using a Zeiss LSM 880 with Airyscan to monitor mitochondrial dynamics.


A computationally-designed inhibitor molecule (gray) interacts snuggly with its target domain (yellow) to prevent cancer-promoting activities.

A computationally-designed inhibitor molecule (gray) interacts snuggly with its target domain (yellow) to prevent cancer-promoting activities.

Research Project 3

Protein Design for Selective Interference with LPA Signaling in Colon Cancer

Gevorg Grigoryan, PhD

Colorectal cancer was the third-most common cause of deaths from cancer in the United States in 2013. This disease claims over 50,000 lives and afflicts over 140,000 people annually in the US, underscoring a clear and urgent need for better control of this incurable malignancy. The goal of our study is to attenuate oncogenic activities in colon cancer cells by inhibiting a key proliferatory signaling pathway mediated by the powerful mitogen lysophosphatidic acid (LPA). Key towards this goal is to produce selective inhibitors—molecules that interact with and inhibit specific proteins in the cell, while avoiding any unintended side-interactions with other proteins. We are uniquely capable of providing such selectivity using computational technologies we have developed that enable us to target selectively a single member in a family of closely related protein domains.